These results indicate that while Gpr18 agonists could have beneficial effects on degenerative and/or inflammatory conditions such as DMD, they could also contribute to the pathogenesis of other conditions, which should be carefully monitored. This evidence concerns the gene GPR18 and Duchenne muscular dystrophy.